With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge has a leading position in most of the product categories offered. The company employs 11,000 people worldwide and the products are sold in more than 130 countries. Getinge has been listed on Nasdaq OMX Stockholm, Nordic Large Cap since 1993 and is included in the OMXS30 index of the 30 most actively traded shares.
The company consists of three business areas.
- Acute Care Therapies offers world-leading solutions for life support in acute health conditions. The offering includes solutions for cardiovascular procedures and a broad selection of products and therapies for intensive care.
- Life Science offers a comprehensive range of equipment, technical expertise and consultation to prevent contamination in pharmaceutical and medical device production and with the aim to strengthen integrity of results in biomedical research.
- Surgical Workflows offers products and solutions to serve as an end-to-end partner for optimizing the quality, safety and capacity usage of the sterile supply departments and operating rooms.
| Currency | SEK |
| Volume | 3,588,159 |
| Previous Close | 211.90 |
| Number of Shares (mil) | 254.15 |
| Change (%) | -8.86 |
| Market Cap (mil) | 53,854.89 |
| Key figures | 2020 | 2021 | 2022 |
|---|---|---|---|
| Order intake, SEK M | 30,568 | 28,258 | 29,621 |
| Net sales, SEK M | 29,819 | 27,049 | 28,292 |
| Adjusted EBITA, SEK M | 5,724 | 5,212 | 4,281 |
| Adjusted EBITA margin, % | 19.2 | 19.3 | 15.1 |
| Adjusted earnings per share, SEK | 14.43 | 13.22 | 10.90 |
| Net debt/equity ratio, multiple | 0.35 | 0.14 | 0.09 |
| Equity/assets ratio, % | 47.7 | 56.5 | 58.5 |
| Equity per share, SEK | 78.9 | 92.4 | 111.8 |
| Return on operating capital, % | 16.3 | 17.3 | 13.0 |
| Return on equity, % | 15.1 | 12.9 | 8.9 |
| Equity/assets ratio, % | 47.7 | 56.5 | 58.5 |
| Net debt/equity ratio, multiple | 0.35 | 0.14 | 0.09 |
| Dividend , SEK | 3.00 | 4.00 | 4.25* |
| Earnings per share, SEK | 11.89 | 10.90 | 9.15 |
| Equity per share, SEK | 78.88 | 92.43 | 111.81 |
| Number of employees, December 31 | 10,818 | 10,729 | 11,082 |
Trends that support the business
- Growing population and longer life expectancy
- Technological innovation
- Collaboration in the healthcare eco system
- Growth in customized drugs
Strategy for sustainable growth
- High standards in quality and sustainability
- Leadership through a strengthened offering
- Use the global brand as a lever
- Capture global growth in underpenetrated areas
- Drive productivity for customers as well as Getinge
- Culture as driver for success – a proud and passionate organisation
Financial targets 2022-2025
- Average organic growth in net sales of 4-6%
- >10% average adjusted EPS growth
Sustainability targets 2022-2025
- >70% index for improved customer quality
- >70% Employee commitment
- All employees trained in business ethics and responsible leadership
Net zero greenhouse gas target is validated
Getinge’s near and long-term targets are aligned with the SBTi's 1.5°C mitigation pathways for reaching net-zero across the value chain by 2050 or sooner according to SBTi’s Target Validation Team. Getinge is committed to reduce absolute scope 1 and 2 greenhouse gas (GHG) emissions 90% by 2030 from a 2021 base year, and to reduce absolute scope 3 GHG emissions 25% within the same timeframe.
